IP Library Granted Patent US 12,433,994
Granted Patent B2
US 12,433,994 · App. 17/688,578 · Granted Oct 7, 2025

Drug delivery device, method of manufacture, and method of use

Inventors: Scott R. Gibson (Granada Hills, CA); Sheldon B. Moberg (Thousand Oaks, CA); Basel Hasan Taha (Westlake Village, CA); Margaux Frances Boyaval (Newbury Park, CA); Mark A. Destefano (Collegeville, PA); John C. Love (San Diego, CA); Ian B. Hanson (Wayne, PA); Paul F. Bente, IV (Wayne, PA); Matthew J. Clemente (Carmel, IN); Rajan Ramaswamy (San Diego, CA); Daniel S. Codd (Escondido, CA); Scott Beaver (San Marcos, CA); Kevin L. Bokelman (San Diego, CA); Sean M. O'connor (West Chester, PA); Robert Decker (Dillsburg, PA); Gautam N. Shetty (Hanover, MD); Ryan M. Agard (Royersford, PA); Nicholas J. Ciccarelli (Philadelphia, PA); Daniel Davenport (Collegeville, PA)
Assignee: AMGEN INC.
A61M5/14248A61M5/142A61M5/14566A61M5/315A61M2005/14252A61M2005/14268A61M2005/2481A61M2205/3368A61M2205/35
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,994
App. No.
17/688,578
Granted
Oct 7, 2025
Kind
B2
Abstract

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.

Claims (33)

1. A wearable drug delivery device comprising:

a housing;

a container disposed at least partially within the housing;

a first seal at least partially covering an opening formed in a wall of the container;

a plunger seal moveably disposed within the container;

a drug disposed within the container, the drug comprising at least one of a granulocyte colony-stimulating factor (G-CSF) or a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) specific antibody;

a drive mechanism configured to move the plunger seal through the container to expel the drug from the container;

a needle having at least: a first position wherein a point of the needle is not disposed through a surface of the first seal, and a second position wherein the point of the needle is disposed through the surface of the first seal into the container;

an insertion mechanism disposed at least partially within the housing, wherein the insertion mechanism comprises:

a rotational biasing member configured to rotate the insertion mechanism housing,

a delivery member connected or configured to be connected in fluid communication with the container, the delivery member being moveable between a first position wherein an insertion portion of the delivery member is positioned within the housing and a second position wherein the insertion portion of the delivery member is positioned exterior to the housing for insertion into a patient,

a hub operably coupled with the delivery member, and

wherein the insertion mechanism housing is operably coupled with the hub such that initial rotation of the insertion mechanism housing causes the delivery member to move axially from the first position to the second position;

an ultraviolet (UV) light source; and

wherein at least a portion of the wearable drug delivery device is configured to facilitate UV sterilization of at least a portion of the surface of the first seal.

2. The wearable drug delivery device of claim 1 , wherein the UV light source is disposed at least partially within the housing.

3. The wearable drug delivery device of claim 1 , wherein the insertion mechanism housing comprises a cylindrical portion and at least a portion of the delivery member is positioned within the cylindrical portion when the delivery member is in the first position.

4. The wearable drug delivery device of claim 1 , wherein the insertion mechanism housing comprises a first guide surface and the hub comprises an outwardly extending follower configured to slidably engage the first guide surface during rotation of the insertion mechanism housing.

5. The wearable drug delivery device of claim 4 , wherein at least a portion of the first guide surface extends in an axial direction and a circumferential direction.

6. The wearable drug delivery device of claim 4 , comprising a second guide surface fixed rotationally with respect to the housing, wherein the outwardly extending follower is configured to slidably engage the second guide surface to facilitate axial movement of the hub during rotation of the insertion mechanism housing.

7. The wearable drug delivery device of claim 1 , wherein the insertion mechanism housing is rotatable about a rotational axis and the rotational axis is parallel to a longitudinal axis of the delivery member.

8. The wearable drug delivery device of claim 7 , wherein the rotational axis of the insertion mechanism housing is coaxial with the longitudinal axis of the delivery member.

9. The wearable drug delivery device of claim 1 , comprising a first abutment member having a first position wherein the first abutment member engages the insertion mechanism housing to prevent the rotational biasing member from rotating the insertion mechanism housing and second position wherein the first abutment member is disengaged from the insertion mechanism housing to allow the rotational biasing member to rotate the insertion mechanism housing.

10. The wearable drug delivery device of claim 9 , wherein the insertion mechanism housing includes a cylindrical portion and a second abutment member extending outwardly from the cylindrical portion, the second abutment member engaging the first abutment member when the first abutment member is in the first position.

11. The wearable drug delivery device of claim 1 , wherein the drive mechanism is configured to expel the drug from the container and into the patient via the delivery member.

12. The wearable drug delivery device of claim 1 , comprising at least one fluid conduit positioned at least partially in the housing and configured to fluidly connect the delivery member and the container, the at least one fluid conduit being coupled to the hub such that at least a portion of the fluid conduit and the hub translate jointly during insertion of the delivery member into the patient.

13. The wearable drug delivery device of claim 1 , wherein the rotational biasing member comprises a torsion spring.

14. The wearable drug delivery device of claim 1 , wherein the delivery member comprises a second needle.

15. The wearable drug delivery device of claim 14 , wherein the second needle has a hollow interior.

16. The wearable drug delivery device of claim 1 , wherein at least a portion of the rotational biasing member surrounds the insertion mechanism housing.

17. The wearable drug delivery device of claim 16 , wherein the insertion mechanism lacks a cover surrounding the rotational biasing member.

18. The wearable drug delivery device of claim 1 , comprising an adhesive applied to a wall of the housing for removably attaching the housing to skin of a patient.

19. The wearable drug delivery device of claim 18 , comprising an opening formed in the wall of the housing, wherein the insertion portion of the delivery member extends through the opening in the second position.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2022
From: DESTEFANO, MARK A.; LOVE, JOHN C.; HANSON, IAN B.; BENTE, PAUL F., IV; CLEMENTE, MATTHEW J., MR.; RAMASWAMY, RAJAN, MR.; CODD, DANIEL S., MR.; BEAVER, SCOTT, MR.; BOKELMAN, KEVIN L., MR.; O'CONNOR, SEAN M., MR.; DECKER, ROBERT, MR.; SHETTY, GAUTAM N., MR.; AGARD, RYAN M.; CICCARELLI, NICHOLAS J., MR.; DAVENPORT, DANIEL, MR.
To: UNITRACT SYRINGE PTY LTD
Reel/Frame 059898/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2022
From: DESTEFANO, MARK A.; LAURENCE, LAWTON; LOVE, JOHN C.; HANSON, IAN B.; BENTE, PAUL F., IV; CLEMENTE, MATTHEW J.; UBACH, ANTONIO; RAMASWAMY, RAJAN; CODD, DANIEL S.; BEAVER, SCOTT; BOKELMAN, KEVIN L.; DARDANI, IAN P.; O'CONNOR, SEAN M.; DECKER, ROBERT; SHETTY, GAUTAM N.; AGARD, RYAN M.; CICCARELLI, NICHOLAS J.; COLLURA, NICHOLAS; WEAVER, MOLLY M.; DAVENPORT, DANIEL; MARLIN, ARTHUR G.; KING, WILLIAM A.; HUROWITZ, STEFANIE A.; CROSS, LEE; DAVIS, MADELINE; KING, ANDREW N.; TRZYBINSKI, ROBERT; KOSSETT, ALEX J.; KORKUCH, DANA K.; FELDMAN, DANIELLE; MAJETTE, MARK; SHAH, JAIMIN B.; MANDES, VINCENT E.; HATCH, CHRISTOPHER EDWARD
To: UNITRACT SYRINGE PTY LTD
Reel/Frame 060199/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2022
From: GIBSON, SCOTT R.; MOBERG, SHELDON B.; TAHA, BASEL HASAN; BOYAVAL, MARGAUX FRANCES
To: AMGEN INC.
Reel/Frame 059298/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2022
From: UNITRACT SYRINGE PTY LTD
To: AMGEN INC.
Reel/Frame 059298/0317 →
Continuity (5)
Continuation 16071873
Provisional Application 62320438 · Apr 8, 2016
Provisional Application 62297718 · Feb 19, 2016
Provisional Application 62294842 · Feb 12, 2016
Related Publication 20220218900A1 · Jul 14, 2022
References Cited (100)
US 4894054A · Miskinyar · 1990 [cited by applicant]
US 5380315A · Isono · 1995 [cited by examiner]
US 7455663B2 · Bikovsky · 2008 [cited by applicant]
US 7708717B2 · Estes et al. · 2010 [cited by applicant]
US 7981085B2 · Ethelfeld · 2011 [cited by applicant]
US 8226610B2 · Edwards et al. · 2012 [cited by applicant]
US 8282601B2 · Mernoe et al. · 2012 [cited by applicant]
US 8668675B2 · Chase et al. · 2014 [cited by applicant]
US 8939935B2 · O'Connor et al. · 2015 [cited by applicant]
US 9061097B2 · Holt et al. · 2015 [cited by applicant]
US 9987419B2 · Hanson et al. · 2018 [cited by applicant]
US 10342918B2 · Politis et al. · 2019 [cited by applicant]
US 20050197625A1 · Haueter et al. · 2005 [cited by applicant]
US 20110066012A1 · Hanson et al. · 2011 [cited by applicant]
US 20120004640A1 · Rosen et al. · 2012 [cited by applicant]
US 20120302844A1 · Schnidrig · 2012 [cited by examiner]
US 20120323183A1 · Peterson · 2012 [cited by examiner]
US 20130006196A1 · Sonderegger et al. · 2013 [cited by applicant]
US 20130060196A1 · O'Connor et al. · 2013 [cited by applicant]
US 20130060233A1 · O'Connor et al. · 2013 [cited by applicant]
US 20130066274A1 · O'Connor · 2013 [cited by examiner]
US 20130237916A1 · Hanson et al. · 2013 [cited by applicant]
US 20130331791A1 · Gross et al. · 2013 [cited by applicant]
US 20140200510A1 · Agard et al. · 2014 [cited by applicant]
US 20140213975A1 · Clemente et al. · 2014 [cited by applicant]
US 20140288511A1 · Tan-Malecki et al. · 2014 [cited by applicant]
US 20140296787A1 · Agard et al. · 2014 [cited by applicant]
US 20140316337A1 · Kadamus et al. · 2014 [cited by applicant]
US 20150057613A1 · Clemente et al. · 2015 [cited by applicant]
US 20150190588A1 · Hanson et al. · 2015 [cited by applicant]
US 20150209505A1 · Hanson et al. · 2015 [cited by applicant]
US 20150217045A1 · Bente, IV et al. · 2015 [cited by applicant]
US 20150290390A1 · Ring et al. · 2015 [cited by applicant]
US 20150297827A1 · Hanson et al. · 2015 [cited by applicant]
US 20150359965A1 · O'Connor et al. · 2015 [cited by applicant]
US 20150374919A1 · Gibson · 2015 [cited by applicant]
US 20160082189A1 · Anderson et al. · 2016 [cited by applicant]
US 20160175515A1 · McCullough · 2016 [cited by applicant]
US 20160175527A1 · McCullough · 2016 [cited by applicant]
US 20170361015A1 · McCullough · 2017 [cited by applicant]
US 20180021508A1 · Destefano et al. · 2018 [cited by applicant]
US 20180028747A1 · Hanson et al. · 2018 [cited by applicant]
US 20180036476A1 · McCullough et al. · 2018 [cited by applicant]
US 20180085517A1 · Laurence et al. · 2018 [cited by applicant]
US 20180353682A1 · Laurence et al. · 2018 [cited by applicant]
EP 1965449A2 · 2008 [cited by applicant]
EP 3260146A1 · 2017 [cited by applicant]
JP S4828863A · 1973 [cited by applicant]
JP S53146489A · 1978 [cited by applicant]
JP 2008245505A · 2008 [cited by applicant]
JP 2010533525A · 2010 [cited by applicant]
JP 2014510571A · 2014 [cited by applicant]
WO WO2009010399A1 · 2009 [cited by applicant]
WO WO2011075100A1 · 2011 [cited by applicant]
WO WO2011133823A1 · 2011 [cited by applicant]
WO WO2013040032A1 · 2013 [cited by applicant]
WO WO2013033467A3 · 2013 [cited by applicant]
WO WO2013033421A3 · 2013 [cited by applicant]
WO WO2014036308A2 · 2014 [cited by applicant]
WO WO2014116274A1 · 2014 [cited by applicant]
WO WO2015027174A4 · 2015 [cited by applicant]
WO WO2015061386A1 · 2015 [cited by applicant]
WO WO2015061389A1 · 2015 [cited by applicant]
WO WO2015091761A1 · 2015 [cited by applicant]
WO WO2015171777A1 · 2015 [cited by applicant]
WO WO2015187793A1 · 2015 [cited by applicant]
WO WO2015187797A1 · 2015 [cited by applicant]
WO WO2015187799A1 · 2015 [cited by applicant]
WO WO2015187802A1 · 2015 [cited by applicant]
WO WO2016003813A1 · 2016 [cited by applicant]
WO WO2016033496A1 · 2016 [cited by applicant]
WO WO2016049501A1 · 2016 [cited by applicant]
WO WO2016049532A1 · 2016 [cited by applicant]
WO WO2015187805A3 · 2016 [cited by applicant]
WO WO2016033507A3 · 2016 [cited by applicant]
WO WO2016053954A8 · 2016 [cited by applicant]
WO WO2016100781A1 · 2016 [cited by applicant]
WO WO2016130679A2 · 2016 [cited by applicant]
WO WO2016133947A1 · 2016 [cited by applicant]
WO WO2016141082A1 · 2016 [cited by applicant]
WO WO2016145094A3 · 2016 [cited by applicant]
WO WO2016186706A1 · 2016 [cited by applicant]
WO WO2017093803A1 · 2017 [cited by applicant]
WO WO2017106247A1 · 2017 [cited by applicant]
WO WO2017139003A1 · 2017 [cited by applicant]
WO WO2017139573A1 · 2017 [cited by applicant]
Uruguay Patent Application No. 37122, Examination Report, dated Jul. 7, 2023. [cited by applicant]
European Patent Application No. 21154819, Communication Pursuant to Article 94(3) EPC, dated Oct. 17, 2023. [cited by applicant]
Taiwan Patent Application No. 110109360, Office Action and Search Report, dated Dec. 7, 2021. [cited by applicant]
Japanese Patent Application No. 2022-078231, Decision of Rejection, mailed Dec. 19, 2023. [cited by applicant]
Australian Patent Application No. 2022203334, Office Action, dated Jun. 15, 2023. [cited by applicant]
U.S. Appl. No. 17/386,659, Nonfinal Office Action, dated May 10, 2023. [cited by applicant]
U.S. Appl. No. 17/386,659, Nonfinal Office Action, dated Jan. 25, 2024. [cited by applicant]
Japanese Patent Application No. 2022-010712, Office Action, dated Jan. 10, 2023. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/026524, mailed Sep. 22, 2017. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/017627, mailed Jul. 27, 2017. [cited by applicant]
Taiwan Patent Application No. 106104660, Office Action and Search Report, dated May 4, 2020. [cited by applicant]
European Patent Application No. 21154819, Extended European Search Report, dated Apr. 29, 2021. [cited by applicant]
U.S. Appl. No. 16/089,685, Nonfinal Office Action, dated Dec. 18, 2020. [cited by applicant]
U.S. Appl. No. 16/071,873, Nonfinal Office Action, dated Jul. 6, 2021. [cited by applicant]